Core Laboratories INC /DE/ Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Disciplined Growth Investors Inc. has reported a beneficial ownership of 3,042,177 shares, representing 6.6% of Core Laboratories Inc.'s common stock as of June 30, 2026.
NYSE
Ariel Investments, LLC has disclosed an increased beneficial ownership of Core Laboratories Inc. common stock, now holding 30.5% of the class.
NYSE
BlackRock, Inc. has updated its Schedule 13G filing, disclosing beneficial ownership of 8.3% of Core Laboratories Inc.'s common stock as of July 31, 2026.
NYSE
Disciplined Growth Investors, Inc. has filed an amendment to its Schedule 13G, reporting a 10.7% beneficial ownership stake in Core Laboratories Inc.
NYSE
The Vanguard Group reports zero beneficial ownership in Core Laboratories Inc. common stock following an internal realignment.
NYSE
EARNEST Partners LLC has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Core Laboratories Inc. /DE/ common stock.
NYSE
Disciplined Growth Investors Inc. reported an increased beneficial ownership of 12.8% in Core Laboratories Inc., holding 5,969,860 common shares.
NYSE
Ariel Investments, LLC has filed an amended Schedule 13G, reporting a 29.4% beneficial ownership stake in Core Laboratories Inc.
NYSE
SCHEDULE: Vanguard Boosts Core Labs Stake to 6.49%
The Vanguard Group has reported an increased beneficial ownership of 6.49% in Core Laboratories Inc., holding over 3 million shares.
NYSE
Disciplined Growth Investors, Inc. has reported an 11.6% beneficial ownership stake in Core Laboratories Inc., holding 5,440,884 common shares.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting a 9.55% beneficial ownership stake in Core Laboratories Inc. as of June 30, 2025.
NYSE
Ariel Investments, LLC has filed an Amendment No. 7 to Schedule 13G, reporting a significant 26.9% beneficial ownership stake in Core Laboratories Inc.
NYSE
Disciplined Growth Investors, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 11.7% of Core Laboratories Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 15.5% Stake in Core Laboratories Inc.
BlackRock, Inc. has filed an amended Schedule 13G, revealing a significant 15.5% beneficial ownership stake in Core Laboratories Inc. /DE/ as of March 31, 2025.
NYSE
Disciplined Growth Investors, Inc. has disclosed a significant 11.7% beneficial ownership stake in Core Laboratories Inc., holding 5,503,651 common shares as of December 31, 2024.